 This is a phase 1, open label study to evaluate the safety and immunogenicity of a single administration of escalating doses of a recombinant replication deficient human adenoviral Ad5 TB vaccine containing the immunodominant antigen Ag85A delivered to the respiratory tract by aerosol in healthy volunteers with a history of BCG immunization. 